Patents by Inventor George Richard Granneman

George Richard Granneman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20210347875
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 11, 2021
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20190055308
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 21, 2019
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20170044249
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: June 19, 2015
    Publication date: February 16, 2017
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K Paulson, Joanna Z. Peng
  • Multiple-variable dose regimen for treating TNF?-related disorders
    Patent number: 8961973
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 24, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
  • Multiple-variable dose regimen for treating TNF?-related disorders
    Patent number: 8961974
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 24, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20140255396
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 11, 2014
    Applicant: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20140248276
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 4, 2014
    Applicant: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20140248275
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 4, 2014
    Applicant: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20140248277
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 4, 2014
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20140212430
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Phillip Yan